TRANSFORMING THE FUTURE

NASDAQ : TINY

FIRST. TRANSFORMATIVE. PROVEN.

1

SAFE HARBOR STATEMENT

This presentation may contain statements of a forward-looking nature relating to future events.Statements contained in this presentation that are forward-looking statements are intended to be madepursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Theseforward-looking statements are subject to the inherent uncertainties in predicting future results andconditions. These statements reflect the Company’s current beliefs, and a number of important factorscould cause actual results to differ materially from those expressed herein.

Please see the Company’s Annual Report on Form 10-K, as well as subsequent filings, filed with theSecurities and Exchange Commission for a more detailed discussion of the risks and uncertaintiesassociated with the Company’s business, including but not limited to the risks and uncertainties associatedwith venture capital investing and other significant factors that could affect the Company’s actual results.Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc. undertakes noobligation to update or revise these forward-looking statements to reflect new events or uncertainties.

2

Harris & Harris Group Builds Transformative Companies

from Disruptive Science

3

CORPORATE MISSION

HARRIS & HARRIS GROUP

• NASDAQ: TINY

• 32 Years on NASDAQ

• NAV/Share: $2.80(1)

4

(1) NAV/Share as of September 30, 2015

COMPANY HIGHLIGHTS

5

• 30-Year History Building Companies

• Holds Equity in Over 20 Transformational Companies

• We Have an Identified Roadmap to Success

• We Identify and Invest in Transformative Growth Markets

• Strong Interdisciplinary Team

• Value Not Yet Realized

Invest

Build ValueReturn

Evergreen Structure Facilitates Growth

• NAV Growth• Company Building• Board Participation• Partnerships

• Early Stage• BIOLOGY+

6

BUSINESS MODEL

OUR COMPETITIVE POSITION

7

Liqu

id

Early-Stage,Active Involvement

Late-StagePassive Involvement

Illiq

uid

Investing in Disruptive Science

Public VC Firms

Public Holding Companies

Private VC Firms

OUR COMPETITIVE POSITION

8

Health Care Technology

BioTherapeutics&

Medical Devices

Health Care Services

Physics

Materials Science

Data & Analytics

Mathematics

Electronics

Engineering

Chemistry

WHY EARLY-STAGE

9

• Opportunity to Generate Outsized Returns

• Addressing Unmet Needs of S&P 500 Corporations

• Limited Competition

• Ability to Influence Company Strategy & Execution

Unique Skillset for Investing in BIOLOGY+

RECOGNIZED LEADERSHIP IN EARLY-STAGE

10

#1 Venture Capital Investor in High-Technology

As measured by GrantIQ’s SBIR Source in February 2014: www.sbirsource.com/sbir/investors

WE HAVE EXPERIENCE BUILDING COMPANIES

Amgen2011

NASDAQ: SZYM 2011

Corden Pharma

2013

Asahi Kasei 2011

Carl Zeiss 2013

Xradia

Ancora

BioVex Crystal ISSolazyme

Canon 2014

Molecular Imprints

Examples of the public markets and/or corporations being interested in our portfolio companies.

OTC: ENUM2014

NYSE: NPTN 2011

NeoPhotonics

Enumeral

DuPont2011

Innovalight

11

WE HAVE BEEN IN TRANSFORMATIVE MARKETS

Solid State Lighting

Drug DeliveryPlant

BioTech

Immuno-Oncology

Additive Manufacturing / Next Gen Semi

Solar

12

RECENT REALIZED EXITS AND LIQUIDITY EVENTS

Notes: Returns on our investments in our publicly traded portfolio companies Enumeral and OpGen are unrealized as of 9/30/15. We may receive additional proceeds from releases of escrowed funds or achievement of milestones related to the sales of Molecular Imprints and BioVex.

NASDAQ: SZYM**

Amgen

NYSE: NPTN

DuPont

Asahi Kasei

OTC: ENUM

(CMOS) CanonCarl Zeiss

Corden

Private Acq.

NASDAQ: OPGN

2012 2013 2014 20152011

Publicly Traded – All/Portion Unrealized as of 9/30/15

CEC

Private Sale

LATEEARLY MID

OpGen*

Magic LeapEnumeral*

Senova

AgBiome

EchoPixel HZO

Nanosys Cambrios

Adesto**

PWA

Ensemble Champions*

Metabolon

BIOLOGY+

Other

NGX BioAccelerator

ORIG3N

Phylagen

ABS

D-WaveMersana

*Publicly traded companies**Publicly traded as of October 27, 2015

ProMuc

TARA Biosystems

WE HAVE POTENTIAL GAME CHANGING PORTFOLIO COMPANIES

14

Note: Equity-focused portfolio companies and stage classifications as of September 30, 2015, not including 1) our rights to milestone payments associated with the acquisitions of BioVex Group, Nextreme Thermal Solutions and Molecular Imprints; and 2) portfolio companies currently in the process of being liquidated, have ceased or are in the process of ceasing operations and/or are seeking a sale of their assets, including Laser Light Engines, Ultora, SynGlyco, Cobalt, Bridgelux, and Black Silicon.

WE ARE NOW IN TRANSFORMATIVE MARKETS

Machine Learning

Regenerative Medicine

AgTech

IoT Health: HZO

Microbiome

Phylagen

Promuc

15

METABOLON

16

• Leader in Metabolomics: 3,000+ Studies, 60+ Patents, $96+ Million Cumulative Revenue

• 2013 Released Three Diagnostic Tests Targeting Diabetes & Cancer

Actionable Diagnosis

• Initial Investment: 2006

• Capital Invested: $ 7.2 Million

• Voting Ownership: 5-10%

• Late Stage

Metabolomics  Measure  

Disease  Status

DNA

RNA

Proteins

Disease/ Treatment

Mechanism

Biochemicals

Genetics  Show  Disease  Risk

D-WAVE

17

• Only Commercial Quantum Computer in the World

• Demonstrating 10,000-100,000x Faster Problem Solving

• Partnered with Lockheed, Google, and NASA

• Initial Investment: 2006

• Capital Invested: $5.8 Million

• Voting Ownership: <2.5%

• Late Stage

*We own voting and non-voting classes of preferred equity of D-Wave Systems, Inc. If the non-voting preferred equity was included in the calculation, our ownership of D-Wave would be in the 2.5-5% range.

HZO

18

• Provides Submersion Protection for Electronic Devices

• Targeting Wearable, Defense, and Mobile Device Markets

• Customers Include Top Brands and Manufacturers including Motorola and Dell

Submersion Protection

• Initial Investment: 2011

• Capital Invested: $8.9 Million

• Voting Ownership: 10-15%

• Mid Stage

Interdisciplinary innovation is required to address these healthcare challenges.

HEALTHCARE TECHNOLOGY

SOLUTIONSBIOLOGY

Electronics

Physics

Materials Science

Chemistry

IT

Engineering

Mathematics

DISTINCTIVE APPROACH

19

BIOLOGY ENABLES H&H PORTFOLIO COMPANY

Engineering Single Cell Analysis

Big DataCrop Protection

Solutions

Physics Predictive Physiology

ITProtein Structure

Analysis

MathematicsHigh-Quality

Molecular Diagnostics

Material Science

Targeted Bio-CompatibleDrug Delivery

A DECADE OF BIOLOGY INVESTMENTS

20

HISTORICAL PARTNERING ECOSYSTEM

21

University Relationships Corporate Relationships

Washington University

Cornell

University of Wisconsin

University College London Tufts

CalTech

University of British Columbia

RPI

Harvard

Arizona State University

University of Texas

University of Minnesota

Columbia MIT

Johns Hopkins University

College of Wooster

Oxford

UC Santa Barbara

University of Toronto

University ofMichigan

UC Berkeley

StanfordPrinceton

Duke

University of Illinois

Cold Spring Harbor Laboratory

SephoraCrucell

BOSCH

3M

Google

Celgene

SyngentaMicrosoft

Health Diagnostic Laboratory, Inc.

LIFE Technologies

Bristol Myers SquibbBunge

Chevron

Coherent

Dow

Genentech

Hitachi Chemical

Illumina

Intel

LG Innotek

Lockheed Martin

Metter Toledo

Mitsui

Panasonic

Samsung

Sanofi-Aventix

SynapticsUnileverTyco

Novartis

Boehringer Ingelheim

Oxford Biosciences

Pfizer

PARTNERING TO BUILD COMPANIES

22

• Cutting Edge Research

• Landscape Analysis

• Foundational Science

• Corporate Demand

• Market Access

• Scale

• Customer Intelligence

• Company Building

• Technology & Deal Sourcing

• Investment Thought Leaders

University Relationships Corporate Relationships

RETURNING VALUE FOR SHAREHOLDERS

23

Generate Meaningful Returns by

Increasing Net Asset Value (NAV) per Share

STRONG INTERDISCIPLINARY TEAM

24

Doug Jamison CEO, Managing Director

Daniel Wolfe, PhDPresident, COO, and Managing Director

• 91 Years of Experience*

• 35 Exits for $2.7 Billion**

• Domain Expertise

Alexei Andreev, PhDEVP, Managing Director

Misti Ushio, PhDCSO, Managing Director

Blake Stevens, PhDVP, Senior Associate

*Includes Investing and Industry experience** Total value of portfolio companies at time of exit without milestone

payments since 2002, when first deal team member joined

COMPANY HIGHLIGHTS

• 30-Year History Building Companies

• Holds Equity in Over 20 Transformational Companies

• We Have an Identified Roadmap to Success

• We Identify and Invest in Transformative Growth Markets

• Strong Interdisciplinary Team

• Value Not Yet Realized

25

CORPORATE MISSION

Harris & Harris Group Builds Transformative Companies from

Disruptive Science

26

27